Cochrane · systematic review · CD010015
Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration
Lawrenson, JG, Evans, JR · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 66.7%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Omega 3 fatty acids compared to placebo for slowing the progression of age‐related macular degeneration
Population: people with AMD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Loss of 3 or more lines of VA at 24 months Omega 3 fatty acids vs placebo | RR 1.14 | 1 study · 236 participants | Moderate Downgraded: imprecision |
Loss of 3 or more lines of VA at 36 months Omega 3 fatty acids vs placebo | RR 1.25 | 1 study · 230 participants | Moderate Downgraded: imprecision |
Incidence of CNV at 24 months Omega 3 fatty acids vs placebo | RR 1.06 | 1 study · 224 participants | Moderate Downgraded: imprecision |
Incidence of CNV at 36 months Omega 3 fatty acids vs placebo | RR 1.12 | 1 study · 195 participants | Moderate Downgraded: imprecision |
Progression of AMD over 5 years Omega 3 fatty acids vs placebo | HR 0.96 [0.84, 1.1] | 2 studies · 2343 participants | High |
Adverse effects Omega 3 fatty acids vs placebo | RR 1.01 | 2 studies · 2343 participants | High |